Kazia Therapeutics Announces Board Changes and AGM Outcomes as It Highlights Oncology Pipeline

The latest update is out from Kazia Therapeutics ( (KZIA) ).

On March 26, 2026, Kazia Therapeutics Limited, a Sydney-based clinical-stage oncology company focused on high-need CNS cancers and aggressive solid tumors, announced that Chairman Bryce Carmine had notified the board of his intention to retire. His resignation, effective March 31, 2026, was accepted without any reported disagreement over company operations or governance, and director Ebru Davidson was appointed to the Audit, Risk and Governance Committee as the board size was reduced from four to three.

At its online Annual General Meeting held on March 25, 2026, shareholders overwhelmingly approved the re-election of director Steven Coffey, with more than 1.05 billion votes cast in favor against a small minority opposing or abstaining. The company also furnished an updated corporate presentation and fact sheet dated March 27, 2026, outlining a well-funded pipeline led by brain-penetrant PI3K/mTOR inhibitor paxalisib and next-generation programs NDL2 and EVT801, underscoring both its financial runway into 2029 and its bid to strengthen its positioning in fast-growing oncology markets.

These governance changes signal an orderly leadership transition at the board level while maintaining continuity through Coffey’s reappointment and Davidson’s committee role. For investors, the refreshed investor materials highlight Kazia’s focus on overcoming treatment resistance in CNS and other aggressive tumors and its cash position of about US$46 million with no debt, suggesting operational stability as it advances clinical and preclinical programs.

The most recent analyst rating on (KZIA) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.

Spark’s Take on KZIA Stock

According to Spark, TipRanks’ AI Analyst, KZIA is a Neutral.

The score is held down primarily by weak financial performance (minimal revenue, large ongoing losses, and persistent cash burn with negative equity). Technicals are a notable offset with strong momentum above major moving averages, but overbought signals add near-term risk; valuation remains challenged due to negative earnings and no dividend support.

To see Spark’s full report on KZIA stock, click here.

More about Kazia Therapeutics

Kazia Therapeutics Limited is a Sydney-based clinical-stage oncology company focused on high-need cancers of the central nervous system and aggressive solid tumors. Founded in 2016, it is developing next-generation therapies including paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor, NDL2, a PD‑L1 protein degrader, and EVT801, a VEGFR3 inhibitor, with approximately US$46 million in cash and no debt as of March 2026.

The company positions its pipeline at the intersection of epigenetic therapeutics, immuno-oncology, and targeted protein degradation, aiming to reprogram cancer biology rather than merely inhibit single pathways. Paxalisib has been evaluated in more than 550 patients across multiple Phase 1–3 trials and expanded access programs, targeting indications such as advanced breast cancer, glioblastoma, and childhood brain cancers.

Kazia’s strategy emphasizes overcoming resistance in aggressive and immunotherapy-refractory cancers through epigenetic and immune reprogramming. Management highlights substantial market opportunities across epigenetic drugs, immuno-oncology, and targeted protein degradation, suggesting its assets are aligned with fast-growing oncology segments and potential partnering opportunities.

Average Trading Volume: 200,068

Technical Sentiment Signal: Sell

Current Market Cap: $82.87M

See more data about KZIA stock on TipRanks’ Stock Analysis page.